News

Sigma extends access to powerful no-code cloudscale data analytics for industry-compliant data cloud so healthcare professionals and researchers can find faster answers to critical questions.

Nanoscope Therapeutics’ Phase 2 STARLIGHT open-label trial enrolled 6 subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.

The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs.

The ScoutPro system allows eye care practices to minimize tech time and seamlessly integrate osmolarity testing into any practice configuration or patient protocol.

According to the company, the NDA submission for Nyxol eye drops in first indication is on track for late 2022.

Haiyan Gong, MD, PhD, professor of ophthalmology and anatomy and neurobiology at Boston University School of Medicine, has received $200,000 through a Standard Award in National Glaucoma Research from the BrightFocus Foundation.

A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.

Zeiss parlays technology into standardization for ophthalmologists and their patients

Spanish investigators from the Ophthalmology Service, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, led by first author Fernando Ly-Yang, MD, reported the case of a 42-year-old man with monkeypox.

The research, presented at the 22nd EURETINA World Congress, outlined that patients with RP experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.

During the 22nd European Society of Retina Specialists Congress in Hamburg, Germany., investigators noted that Yusar and colleagues from the Vitreoretinal Services, Centre for Sight, Delhi, India.

Oral ZPX3330 found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 Prior Trials of APX3330.

According to the company, the Phase 3 pivotal trials met pre-specified primary efficacy endpoints for both doses of iDose TR., supported an anticipated upcoming NDA submission.

Elisabeth J. Cohen, MD, has been appointed vice chair for academic affairs, enhancing the department’s commitment to research and advancing its reputation for excellence in studying and treating diseases of the eye.

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

Craig Morgan, MD, and Eye Consultants of Huntington, West Virginia, paid $907,074.64 to resolve allegations that they submitted false claims to Medicare and Medicaid, the U.S. Attorney’s Office for the Southern District of West Virginia reported.

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

If approved, TP-03 may offer treatment for millions of patients with Demodex blepharitis. TP-03 is now also being studied for the treatment of Meibomian Gland Disease in patients with Demodex mites.

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.

According to a presentation by the company at the 22nd EURETINA World Congress in Hamburg, Germany, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

According to a university news release, its CellSight teams clinched top two of three awards in National Eye Institute competition.

According to an OHSA investigator, a study shows changes in patient volume, billing after private equity firms acquire physician practices.

Surveys have found that burnout among physicians who deliver “primary care” is so bad that 20% of them intend to stop practicing.

A study detailed at the 22nd EURETINA Congress in Hamburg, Germany, documented a spectrum of manifestations following COVID-19 infections in an otherwise immunocompetent patient presenting at a tertiary care center.